JEFFREY E GERSHENWALD

TitleProfessor
InstitutionMD Anderson
DepartmentSurgical Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880. PMID: 34777916.
      Citations:    
    2. Sloane RAS, White MG, Witt RG, Banerjee A, Davies MA, Han G, Burton E, Ajami N, Simon JM, Bernatchez C, Haydu LE, Tawbi HA, Gershenwald JE, Keung E, Ross M, McQuade J, Amaria RN, Wani K, Lazar AJ, Woodman SE, Wang L, Andrews MC, Wargo JA. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21). PMID: 34771465.
      Citations:    
    3. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441. PMID: 34239137.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    4. Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Basen-Engquist K, Gershenwald JE, Tektiridis JH, Moreno M, Williams PA, Treiman K, Garza PD, Hawk E. Be Well Communities™: mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control. 2021 Aug; 32(8):859-870. PMID: 34037915.
      Citations:    Fields:    Translation:HumansPHPublic Health
    5. Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DY. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep. 2021 04 27; 11(1):9043. PMID: 33907234.
      Citations: 2     Fields:    Translation:Humans
    6. Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489. PMID: 33856603.
      Citations: 1     Fields:    Translation:Humans
    7. Gershenwald JE. Active surveillance of patients who have melanoma with a positive sentinel node in an era of effective adjuvant therapy: Early lessons learned … and still learning. Cancer. 2021 Jul 01; 127(13):2177-2180. PMID: 33826746.
      Citations:    Fields:    
    8. Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 04 07; 19(1):142. PMID: 33827575.
      Citations: 1     Fields:    Translation:Humans
    9. Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gershenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697. PMID: 33414132.
      Citations: 2     Fields:    Translation:Humans
    10. Fischer GM, Carapeto FCL, Joon AY, Haydu LE, Chen H, Wang F, Van Arnam JS, McQuade JL, Wani K, Kirkwood JM, Thompson JF, Tetzlaff MT, Lazar AJ, Tawbi HA, Gershenwald JE, Scolyer RA, Long GV, Davies MA. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661. PMID: 33016647.
      Citations: 1     Fields:    Translation:HumansCells
    11. Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011. PMID: 32725204.
      Citations: 8     Fields:    Translation:Humans
    12. Keung EZ, Gershenwald JE. Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. J Natl Cancer Inst. 2020 09 01; 112(9):875-885. PMID: 32061122.
      Citations: 6     Fields:    Translation:Humans
    13. Day RW, Taylor BM, Bednarski BK, Tzeng CD, Gershenwald JE, Lee JE, Grubbs EG. Virtual Interviews for Surgical Training Program Applicants During COVID-19: Lessons Learned and Recommendations. Ann Surg. 2020 08; 272(2):e144-e147. PMID: 32675519.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    14. Tetzlaff MT, Adhikari C, Lo S, Rawson RV, Amaria RN, Menzies AM, Wilmott JS, Ferguson PM, Ross MI, Spillane AJ, Vu KA, Ma J, Ning J, Haydu LE, Saw RPM, Wargo JA, Tawbi HA, Gershenwald JE, Long GV, Davies MA, Scolyer RA. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020 11; 31(11):1569-1579. PMID: 32739408.
      Citations:    Fields:    Translation:Humans
    15. Lo SN, Ma J, Scolyer RA, Haydu LE, Stretch JR, Saw RPM, Nieweg OE, Shannon KF, Spillane AJ, Ch'ng S, Mann GJ, Gershenwald JE, Thompson JF, Varey AHR. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020 08 20; 38(24):2719-2727. PMID: 32530761.
      Citations: 8     Fields:    Translation:Humans
    16. Tzeng CD, Tran Cao HS, Roland CL, Teshome M, Bednarski BK, Ikoma N, Graham PH, Keung EZ, Scally CP, Katz MHG, Gershenwald JE, Lee JE, Vauthey JN. Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. Surg Oncol. 2020 Sep; 34:182-185. PMID: 32891326.
      Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
    17. Ascierto PA, Agarwala SS, Eggermont A, Gershenwald JE, Grob JJ, Hamid O, Michielin O, Postow M, Puzanov I, Zarour HM, Caracò C, Testori A. The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019. J Transl Med. 2020 04 16; 18(1):171. PMID: 32299446.
      Citations: 1     Fields:    Translation:Humans
    18. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895. PMID: 32015020.
      Citations: 11     Fields:    Translation:HumansCells
    19. Rosenbaum SR, Knecht M, Mollaee M, Zhong Z, Erkes DA, McCue PA, Chervoneva I, Berger AC, Lo JA, Fisher DE, Gershenwald JE, Davies MA, Purwin TJ, Aplin AE. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 01 14; 30(2):510-524.e6. PMID: 31940493.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    20. Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438. PMID: 31870188.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    21. Scolyer RA, Rawson RV, Gershenwald JE, Ferguson PM, Prieto VG. Melanoma pathology reporting and staging. Mod Pathol. 2020 01; 33(Suppl 1):15-24. PMID: 31758078.
      Citations: 12     Fields:    Translation:Humans
    22. Abudu B, Cook KA, Gershenwald JE, Cohen PR, Geller AC. Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer. 2020 02 15; 126(4):775-781. PMID: 31714593.
      Citations: 2     Fields:    Translation:Humans
    23. Scolyer RA, Gershenwald JE, Thompson JF. Isolated Imunohistochemistry-positive Cells Without Morphologic Characteristics of Melanoma Should Not Result in Designation as a Positive Sentinel Lymph Node According to the AJCC 8th Edition Staging System. Am J Surg Pathol. 2019 10; 43(10):1442-1444. PMID: 31306154.
      Citations:    Fields:    Translation:Humans
    24. Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres-Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross M, Gershenwald JE, Prieto VG. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593. PMID: 31570567.
      Citations: 3     Fields:    Translation:Humans
    25. Malke JC, Jin S, Camp SP, Lari B, Kell T, Simon JM, Prieto VG, Gershenwald JE, Haydu LE. Enhancing Case Capture, Quality, and Completeness of Primary Melanoma Pathology Records via Natural Language Processing. JCO Clin Cancer Inform. 2019 08; 3:1-11. PMID: 31442076.
      Citations: 2     Fields:    Translation:Humans
    26. Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389. PMID: 31267972.
      Citations: 31     Fields:    Translation:Humans
    27. Lillemoe HA, Scally CP, Adams CL, Bednarski BK, Balch CM, Aloia TA, Gershenwald JE, Lee JE, Grubbs EG. Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Ann Surg Oncol. 2019 Sep; 26(9):2667-2674. PMID: 31168736.
      Citations:    Fields:    Translation:Humans
    28. Haydu LE, Thompson JF, Scolyer RA, Gershenwald JE. Embracing changes to the American Joint Committee on Cancer 8th edition melanoma staging system. Eur J Cancer. 2019 05; 112:9-11. PMID: 30884440.
      Citations: 2     Fields:    Translation:Humans
    29. Asare EA, Grubbs EG, Gershenwald JE, Greene FL, Aloia TA. Setting the "stage" for Surgical Oncology fellows: Pierre Denoix and TNM staging. J Surg Oncol. 2019 Jun; 119(7):823. PMID: 30729519.
      Citations:    Fields:    Translation:Humans
    30. Nelson KC, Gershenwald JE, Savory SA, Wilson JM, Simon JM, Burton EM, Haydu LE. Telementoring and smartphone-based answering systems to optimize dermatology resident dermoscopy education. J Am Acad Dermatol. 2019 Aug; 81(2):e27-e28. PMID: 30703459.
      Citations: 3     Fields:    Translation:Humans
    31. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941. PMID: 30361510.
      Citations:    Fields:    
    32. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942. PMID: 30361511.
      Citations: 2     Fields:    
    33. Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 01; 80(1):208-250. PMID: 30392755.
      Citations: 52     Fields:    Translation:Humans
    34. Curry JL, Tetzlaff MT, Wang SA, Landon G, Alouch N, Patel SP, Nagarajan P, Gupta S, Aung PP, Devine CE, Khoury JD, Loghavi S, Prieto VG, DiNardo CD, Gershenwald JE. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835. PMID: 29863571.
      Citations:    Fields:    Translation:Humans
    35. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654. PMID: 30297909.
      Citations: 168     Fields:    Translation:HumansCTClinical Trials
    36. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44. PMID: 30281145.
      Citations: 7     Fields:    Translation:HumansAnimals
    37. Bhutiani N, Egger ME, Stromberg AJ, Gershenwald JE, Ross MI, Philips P, Martin RCG, Scoggins CR, McMasters KM. A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. J Surg Oncol. 2018 Nov; 118(6):922-927. PMID: 30259521.
      Citations: 2     Fields:    Translation:Humans
    38. Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868. PMID: 29945191.
      Citations: 25     Fields:    Translation:Humans
    39. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018 08; 18(8):775-784. PMID: 29923435.
      Citations: 17     Fields:    Translation:Humans
    40. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol. 2018; 2018. PMID: 31058252.
      Citations: 8     
    41. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428. PMID: 29848573.
      Citations: 29     Fields:    Translation:HumansCells
    42. LoConte NK, Gershenwald JE, Thomson CA, Crane TE, Harmon GE, Rechis R. Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:88-100. PMID: 30231343.
      Citations: 6     Fields:    Translation:HumansPHPublic Health
    43. Ferguson PM, Gershenwald JE, Scolyer RA. Staging of Cutaneous Melanoma: Is There Room for Further Improvement? JAMA Netw Open. 2018 05 18; 1(1):e180086. PMID: 30646045.
      Citations:    Fields:    Translation:Humans
    44. Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M. Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma. Clin Cancer Res. 2018 09 01; 24(17):4119-4125. PMID: 29776954.
      Citations: 5     Fields:    Translation:Humans
    45. Zabor EC, Coit D, Gershenwald JE, McMasters KM, Michaelson JS, Stromberg AJ, Panageas KS. Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. Ann Surg Oncol. 2018 Aug; 25(8):2172-2177. PMID: 29470818.
      Citations: 2     Fields:    Translation:Humans
    46. Namikawa K, Aung PP, Gershenwald JE, Milton DR, Prieto VG. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018 03; 7(3):583-593. PMID: 29464914.
      Citations: 12     Fields:    Translation:Humans
    47. McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322. PMID: 29449192.
      Citations: 150     Fields:    Translation:Humans
    48. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193. PMID: 29361468.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    49. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2018 01 08; 33(1):151. PMID: 29316429.
      Citations: 30     Fields:    
    50. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017 08 14; 32(2):204-220.e15. PMID: 28810145.
      Citations: 209     Fields:    Translation:HumansCells
    51. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Wargo J, Haydu LE, Davies MA, McQuade JL, Sui D, Bassett RL, Reveille JD, Wei Q, Amos CI, Lee JE. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795. PMID: 28442307.
      Citations: 15     Fields:    Translation:Humans
    52. Gershenwald JE, Nelson KC. Skin Cancer: Have melanoma and skin cancer finally met their match? Nat Rev Clin Oncol. 2017 05; 14(5):267-268. PMID: 28422116.
      Citations:    Fields:    Translation:Humans
    53. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565.
      Citations: 48     
    54. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379). PMID: 28251903.
      Citations: 226     Fields:    Translation:HumansCells
    55. Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, Peterson SK. Assessment of Compliance With Texas Legislation Banning Indoor UV Tanning by Minors. JAMA Dermatol. 2017 Feb 01; 153(2):228-229. PMID: 27829081.
      Citations: 6     Fields:    
    56. Roife D, Kang Y, Wang L, Fang B, Swisher SG, Gershenwald JE, Pretzsch S, Dinney CP, Katz MHG, Fleming JB. Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. Surgery. 2017 05; 161(5):1246-1254. PMID: 28081955.
      Citations: 7     Fields:    Translation:HumansAnimals
    57. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28591523.
      Citations: 179     Fields:    Translation:HumansCTClinical Trials
    58. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29665799.
      Citations: 1     Fields:    Translation:Humans
    59. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29850954.
      Citations: 72     Fields:    Translation:Humans
    60. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27067306.
      Citations: 8     Fields:    Translation:Humans
    61. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28094848.
      Citations: 788     Fields:    Translation:Humans
    62. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29028110.
      Citations: 340     Fields:    Translation:Humans
    63. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30115691.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    64. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30105437.
      Citations: 2     Fields:    
    65. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27087480.
      Citations: 33     Fields:    Translation:HumansCells
    66. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29097493.
      Citations: 878     Fields:    Translation:HumansAnimals
    67. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26477877.
      Citations: 5     Fields:    Translation:Humans
    68. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26645196.
      Citations: 449     Fields:    Translation:HumansAnimalsCells
    69. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25348889.
      Citations: 8     Fields:    Translation:Humans
    70. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25848976.
      Citations: 4     Fields:    Translation:Humans
    71. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25659743.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    72. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 10791854.
      Citations: 5     Fields:    Translation:Humans
    73. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11504744.
      Citations: 449     Fields:    Translation:Humans
    74. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15389473.
      Citations: 22     Fields:    Translation:Humans
    75. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14764994.
      Citations: 1     Translation:HumansCells
    76. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16034040.
      Citations: 16     Fields:    Translation:Humans
    77. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16538172.
      Citations: 17     Fields:    Translation:Humans
    78. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23838920.
      Citations: 40     Fields:    Translation:Humans
    79. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23922205.
      Citations: 34     Fields:    Translation:Humans
    80. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23752305.
      Citations: 8     Fields:    Translation:Humans
    81. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24097199.
      Citations: 11     Fields:    Translation:Humans
    82. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24369020.
      Citations: 3     Fields:    Translation:Humans
    83. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21111956.
      Citations: 44     Fields:    Translation:Humans
    84. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21647761.
      Citations: 22     Fields:    Translation:Humans
    85. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21480247.
      Citations: 14     Fields:    Translation:Humans
    86. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19917835.
      Citations: 1286     Fields:    Translation:Humans
    87. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21111959.
      Citations: 1     Fields:    Translation:Humans
    88. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23901115.
      Citations: 78     Fields:    Translation:HumansCells
    89. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16538410.
      Citations: 35     Fields:    Translation:Humans
    90. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22488042.
      Citations: 10     Fields:    Translation:HumansCells
    91. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16256927.
      Citations: 2     Fields:    Translation:Humans
    92. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17671814.
      Citations: 12     Fields:    Translation:Humans
    93. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18206850.
      Citations: 17     Fields:    Translation:Humans
    94. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19430405.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    95. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18922915.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    96. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21047771.
      Citations: 22     Fields:    Translation:HumansCells
    97. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21295201.
      Citations: 10     Fields:    Translation:Humans
    98. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22453020.
      Citations: 8     Fields:    Translation:Humans
    99. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16322269.
      Citations: 29     Fields:    Translation:HumansCells
    100. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16621887.
      Citations: 24     Fields:    Translation:Humans
    101. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18813315.
      Citations: 110     Fields:    Translation:HumansCells
    102. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20187100.
      Citations: 31     Fields:    Translation:Humans
    103. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20369298.
      Citations: 9     Fields:    Translation:Humans
    104. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21081714.
      Citations: 70     Fields:    Translation:HumansPHPublic Health
    105. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22198560.
      Citations: 10     Fields:    Translation:HumansCells
    106. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22342785.
      Citations: 4     Fields:    Translation:Humans
    107. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21946352.
      Citations: 74     Fields:    Translation:Humans
    108. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23407396.
      Citations: 26     Fields:    Translation:HumansCells
    109. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30863861.
      Citations: 7     Fields:    Translation:Humans
    110. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30737667.
      Citations:    Fields:    Translation:Humans
    111. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30787016.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    112. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31176707.
      Citations: 11     Fields:    Translation:HumansCells
    113. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31383963.
      Citations: 2     Fields:    Translation:Humans
    114. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31630191.
      Citations: 1     Fields:    Translation:Humans
    115. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31942075.
      Citations: 340     Fields:    Translation:HumansCells
    116. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31990608.
      Citations: 3     Fields:    Translation:Humans
    117. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32374709.
      Citations:    Translation:Humans
    118. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33454993.
      Citations:    Fields:    Translation:Humans
    119. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33463835.
      Citations:    Fields:    Translation:Humans
    120. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33484834.
      Citations:    Fields:    Translation:Humans
    121. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33577643.
      Citations:    Fields:    
    122. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, Woodman SE, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381. PMID: 27911979.
      Citations: 13     Fields:    Translation:Humans
    123. Nagarajan P, Curry JL, Ning J, Piao J, Torres-Cabala CA, Aung PP, Ivan D, Ross MI, Levenback CF, Frumovitz M, Gershenwald JE, Davies MA, Malpica A, Prieto VG, Tetzlaff MT. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104. PMID: 27864417.
      Citations: 13     Fields:    Translation:Humans
    124. Gershenwald JE, Halpern AC, Sondak VK. Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. JAMA. 2016 Nov 08; 316(18):1913-1914. PMID: 27824997.
      Citations: 2     Fields:    Translation:Humans
    125. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med. 2016 10 25; 14(1):168. PMID: 27776519.
      Citations: 47     Fields:    Translation:HumansCells
    126. Fang S, Vaysse A, Brossard M, Wang Y, Deng D, Liu Q, Zhang P, Xu K, Li M, Feng R, Liu H, Dang Y, Chen W, Prieto V, Gershenwald JE, Ross MI, Matejka B, Malke J, Haydu LE, Reveille JD, Sui D, Bassett RL, Koshkina N, Avril MF, Lu M, Wei Q, Demenais F, Amos CI, Lee JE. Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. J Invest Dermatol. 2017 01; 137(1):253-257. PMID: 27506587.
      Citations: 2     Fields:    Translation:Humans
    127. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722.
      Citations: 304     Fields:    Translation:HumansCells
    128. Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016 09; 108(9). PMID: 27245173.
      Citations: 33     Fields:    Translation:Humans
    129. Najita JS, Swetter SM, Geller AC, Gershenwald JE, Zelen M, Lee SJ. Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol. 2016 09; 136(9):1894-1897. PMID: 27251792.
      Citations: 3     Fields:    Translation:Humans
    130. Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016 Nov 12; 66(6):460-480. PMID: 27232110.
      Citations: 45     Fields:    
    131. Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PA. Critical Assessment of Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 09; 23(9):2753-61. PMID: 27052645.
      Citations: 12     Fields:    Translation:Humans
    132. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7. PMID: 24977319.
      Citations: 1     Fields:    Translation:Humans
    133. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7. PMID: 27001565.
      Citations: 23     Fields:    Translation:Humans
    134. Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA. Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073. PMID: 26986135.
      Citations: 19     Fields:    Translation:Humans
    135. McMasters KM, Egger ME, Edwards MJ, Ross MI, Reintgen DS, Noyes RD, Martin RC, Goydos JS, Beitsch PD, Urist MM, Ariyan S, Sussman JJ, Davidson BS, Gershenwald JE, Hagendoorn LJ, Stromberg AJ, Scoggins CR. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86. PMID: 26858331.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    136. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044. PMID: 27141370.
      Citations: 23     
    137. Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin. 2016 09; 66(5):370-4. PMID: 26784705.
      Citations: 68     Fields:    Translation:Humans
    138. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24. PMID: 26783288.
      Citations: 19     Fields:    Translation:Humans
    139. Boland GM, Gershenwald JE. Principles of Melanoma Staging. Cancer Treat Res. 2016; 167:131-48. PMID: 26601861.
      Citations: 9     Fields:    Translation:Humans
    140. Watson M, Thomas CC, Massetti GM, McKenna S, Gershenwald JE, Laird S, Iskander J, Lushniak B. CDC Grand Rounds: Prevention and Control of Skin Cancer. MMWR Morb Mortal Wkly Rep. 2015 Dec 04; 64(47):1312-4. PMID: 26633233.
      Citations: 3     Fields:    Translation:Humans
    141. Gershenwald JE, Guy GP. Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. J Natl Cancer Inst. 2016 Jan; 108(1). PMID: 26563358.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    142. Bulger AL, Mayer JE, Gershenwald JE, Guild SR, Gottlieb MA, Geller AC. Enforcement Provisions of Indoor Tanning Bans for Minors: An Analysis of the First 6 US States. Am J Public Health. 2015 Aug; 105(8):e10-2. PMID: 26066916.
      Citations: 6     Fields:    Translation:Humans
    143. Asare EA, Washington MK, Gress DM, Gershenwald JE, Greene FL. Improving the quality of cancer staging. CA Cancer J Clin. 2015 Jul-Aug; 65(4):261-3. PMID: 25952338.
      Citations: 9     Fields:    Translation:Humans
    144. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10. PMID: 26058727.
      Citations: 12     Fields:    Translation:Humans
    145. Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A. Melanoma. Nat Rev Dis Primers. 2015 04 23; 1:15003. PMID: 27188223.
      Citations: 127     Fields:    Translation:HumansCells
    146. Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015 Sep; 24(5):724-33. PMID: 25809989.
      Citations: 7     Fields:    Translation:Humans
    147. Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96. PMID: 25779565.
      Citations: 19     Fields:    Translation:Humans
    148. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21. PMID: 25686251.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    149. Gottlieb M, Balk SJ, Geller AC, Gershenwald JE. Teens and indoor tanning: time to act on the US Food and Drug Administration's black-box warning. Ann Surg Oncol. 2015 Mar; 22(3):701-3. PMID: 25515195.
      Citations: 1     Fields:    Translation:Humans
    150. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2015 Apr 15; 136(8):1874-80. PMID: 25196740.
      Citations: 3     Fields:    Translation:Humans
    151. Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S, Flaherty KT, Carvajal RD. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015 Mar; 28(2):135-47. PMID: 25113308.
      Citations: 31     Fields:    Translation:HumansCells
    152. Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36. PMID: 25165098.
      Citations: 55     Fields:    Translation:Humans
    153. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515. PMID: 25148578.
      Citations: 48     Fields:    Translation:Humans
    154. Rueth NM, Xing Y, Chiang YJ, Cromwell KD, Ross MI, Lee JE, Gershenwald JE, Royal RE, Cormier JN. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22. PMID: 24096759.
      Citations: 16     Fields:    Translation:Humans
    155. Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y. A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget. 2014 May 30; 5(10):2912-7. PMID: 24913145.
      Citations: 26     Fields:    Translation:HumansCells
    156. Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VK. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81. PMID: 24531700.
      Citations: 30     Fields:    Translation:Humans
    157. Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med. 2014 Feb 13; 370(7):663-4. PMID: 24521113.
      Citations: 7     Fields:    Translation:Humans
    158. Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, Yu SS, Johnson TM, Liegeois NJ, Byrd D, Sober A, Nghiem P. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol. 2014 Apr; 70(4):637-643. PMID: 24521828.
      Citations: 23     Fields:    Translation:Humans
    159. Curry JL, Davies MA, Calderone TL, Nathanson K, Prieto VG, Gershenwald JE. Tissue resources for clinical use and marker studies in melanoma. Methods Mol Biol. 2014; 1102:679-95. PMID: 24259006.
      Citations: 2     Fields:    Translation:HumansCells
    160. Prickett TD, Zerlanko B, Gartner JJ, Parker SCJ, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y. Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin. J Invest Dermatol. 2014 Feb; 134(2):452-460. PMID: 24008424.
      Citations: 10     Fields:    Translation:HumansCells
    161. Ross MI, Gershenwald JE. Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. Clin Dermatol. 2013 May-Jun; 31(3):298-310. PMID: 23608449.
      Citations: 6     Fields:    Translation:Humans
    162. Slingluff CL, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, Smolkin ME, Olson WC, Gaucher A, Chase CM, Grosh WW, Weiss GR, Wagenseller AG, Olszanski AJ, Martin L, Shea SM, Erdag G, Ram P, Gershenwald JE, Weber MJ. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 01; 19(13):3611-20. PMID: 23620404.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    163. Guan X, Niu J, Liu Z, Wang LE, Amos CI, Lee JE, Gershenwald JE, Grimm EA, Wei Q. Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res. 2013 May; 26(3):422-5. PMID: 23360207.
      Citations: 1     Fields:    Translation:HumansCells
    164. Cheng CS, Rai K, Garber M, Hollinger A, Robbins D, Anderson S, Macbeth A, Tzou A, Carneiro MO, Raychowdhury R, Russ C, Hacohen N, Gershenwald JE, Lennon N, Nusbaum C, Chin L, Regev A, Amit I. Semiconductor-based DNA sequencing of histone modification states. Nat Commun. 2013; 4:2672. PMID: 24157732.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    165. Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714536.
      Citations: 8     Fields:    Translation:Humans
    166. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70. PMID: 23032743.
      Citations: 154     Fields:    Translation:HumansCellsCTClinical Trials
    167. Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JN. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012 Oct; 22(5):376-85. PMID: 22914178.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    168. Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol. 2012 Oct; 19(11):3301-3. PMID: 22868918.
      Citations: 9     Fields:    Translation:Humans
    169. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63. PMID: 22817889.
      Citations: 1004     Fields:    Translation:HumansCells
    170. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296.
      Citations: 4     Fields:    Translation:HumansAnimals
    171. Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol. 2012 May; 180(5):2170-81. PMID: 22465753.
      Citations: 13     Fields:    Translation:HumansCells
    172. Chodkiewicz HM, Cohen PR, Kim KB, Ivan D, Gershenwald JE. A lupus-like reaction to subcutaneous interferon-a at injection sites. J Drugs Dermatol. 2012 Mar; 11(3):393-8. PMID: 22395592.
      Citations:    Fields:    Translation:Humans
    173. Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, Lazar AJ, Hwu P, Davies MA. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012 Aug 15; 118(16):4014-23. PMID: 22180178.
      Citations: 229     Fields:    Translation:Humans
    174. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42. PMID: 22049339.
      Citations: 36     Fields:    Translation:HumansCells
    175. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV, Fang S, Kosoy R, Zhang M, Qureshi AA, Vattathil S, Schacherer CW, Gardner JM, Wang Y, Bishop DT, Barrett JH, MacGregor S, Hayward NK, Martin NG, Duffy DL, Mann GJ, Cust A, Hopper J, Brown KM, Grimm EA, Xu Y, Han Y, Jing K, McHugh C, Laurie CC, Doheny KF, Pugh EW, Seldin MF, Han J, Wei Q. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011 Dec 15; 20(24):5012-23. PMID: 21926416.
      Citations: 110     Fields:    Translation:HumansCells
    176. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011 Sep; 104(4):341-53. PMID: 21858828.
      Citations: 11     Fields:    Translation:Humans
    177. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011 Sep; 104(4):379-85. PMID: 21858832.
      Citations: 30     Fields:    Translation:Humans
    178. Askew RL, Swartz RJ, Xing Y, Cantor SB, Ross MI, Gershenwald JE, Palmer JL, Lee JE, Cormier JN. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6. PMID: 21914512.
      Citations: 17     Fields:    Translation:Humans
    179. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91. PMID: 21632855.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    180. Moore-Olufemi S, Herzog C, Warneke C, Gershenwald JE, Mansfield P, Ross M, Prieto V, Lally KP, Hayes-Jordan A. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg. 2011 Jun; 253(6):1211-5. PMID: 21451389.
      Citations: 11     Fields:    Translation:Humans
    181. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011 May 05; 364(18):1738-45. PMID: 21542744.
      Citations: 24     Fields:    Translation:Humans
    182. Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC, Sleeman JP, Gershenwald JE. Lymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol. 2011 May 01; 103(6):489-500. PMID: 21480241.
      Citations: 11     Fields:    Translation:Humans
    183. Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011 Jun 01; 29(16):2199-205. PMID: 21519009.
      Citations: 72     Fields:    Translation:Humans
    184. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011 May; 43(5):442-6. PMID: 21499247.
      Citations: 251     Fields:    Translation:HumansCells
    185. Gershenwald JE. Preface. Melanoma. Surg Oncol Clin N Am. 2011 Jan; 20(1):xv-xvi. PMID: 21111955.
      Citations:    Fields:    Translation:Humans
    186. Davies MA, Gershenwald JE. Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am. 2011 Jan; 20(1):165-80. PMID: 21111965.
      Citations: 9     Fields:    Translation:HumansCells
    187. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011 Jan 15; 17(2):229-35. PMID: 20975100.
      Citations: 89     Fields:    Translation:Humans
    188. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15. PMID: 20655738.
      Citations: 4     Fields:    Translation:Humans
    189. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov; 63(5):751-61. PMID: 20646783.
      Citations: 141     Fields:    Translation:Humans
    190. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM staging system for cutaneous melanoma...and beyond. Ann Surg Oncol. 2010 Jun; 17(6):1475-7. PMID: 20300965.
      Citations: 35     Fields:    Translation:HumansCells
    191. Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol. 2010 Aug; 17(8):2006-14. PMID: 20379784.
      Citations: 32     Fields:    Translation:Humans
    192. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9. PMID: 20368546.
      Citations: 114     Fields:    Translation:Humans
    193. Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72. PMID: 20336388.
      Citations: 24     Fields:    Translation:Humans
    194. Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR. Constitutive expression of the alpha4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia. 2010 Feb; 12(2):173-82. PMID: 20126475.
      Citations: 21     Fields:    Translation:AnimalsCells
    195. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15; 15(24):7538-7546. PMID: 19996208.
      Citations: 105     Fields:    
    196. Scoggins CR, Martin RC, Ross MI, Edwards MJ, Reintgen DS, Urist MM, Gershenwald JE, Sussman JJ, Dirk Noyes R, Goydos JS, Beitsch PD, Ariyan S, Stromberg AJ, Hagendoorn LJ, McMasters KM. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010 Mar; 17(3):709-17. PMID: 19967459.
      Citations: 21     Fields:    Translation:Humans
    197. Berman RS, Kurtzman SH, Posner MC, Gershenwald JE. Society of surgical oncology fellowship training: where we have been, where we are now, and where we are going. J Surg Oncol. 2009 Sep 01; 100(3):179-81. PMID: 19444817.
      Citations: 1     Fields:    Translation:Humans
    198. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009 Jun 01; 115(11):2505-13. PMID: 19309746.
      Citations: 11     Fields:    Translation:Humans
    199. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP. CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009 Jun; 19(3):146-55. PMID: 19441164.
      Citations: 39     Fields:    Translation:HumansCells
    200. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May; 60(5):872-5. PMID: 19389531.
      Citations: 26     Fields:    Translation:Humans
    201. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009 Mar; 7(3):308-17. PMID: 19401063.
      Citations: 19     Fields:    Translation:Humans
    202. Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol. 2009 Nov; 36(11):1157-63. PMID: 19222695.
      Citations: 13     Fields:    Translation:Humans
    203. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51. PMID: 18563783.
      Citations: 24     Fields:    Translation:Humans
    204. Beadle BM, Guadagnolo BA, Ballo MT, Lee JE, Gershenwald JE, Cormier JN, Mansfield PF, Ross MI, Zagars GK. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82. PMID: 18774657.
      Citations: 9     Fields:    Translation:Humans
    205. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40. PMID: 18728664.
      Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
    206. Gershenwald JE, Petrelli N. Fellowship training in surgical oncology--an international affair. Surg Oncol. 2008 Dec; 17(4):277-9. PMID: 18672361.
      Citations: 1     Fields:    Translation:Humans
    207. Gershenwald JE, Andtbacka RH, Prieto VG, Johnson MM, Diwan AH, Lee JE, Mansfield PF, Cormier JN, Schacherer CW, Ross MI. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303. PMID: 18606982.
      Citations: 31     Fields:    Translation:Humans
    208. Mortenson MM, Xing Y, Weaver S, Lee JE, Gershenwald JE, Lucci A, Mansfield PF, Ross MI, Cormier JN. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63. PMID: 18564433.
      Citations: 9     Fields:    Translation:Humans
    209. Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res. 2008 Jun 01; 68(11):4392-7. PMID: 18519701.
      Citations: 19     Fields:    Translation:Humans
    210. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57. PMID: 18383513.
      Citations: 19     Fields:    Translation:Humans
    211. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7. PMID: 18320602.
      Citations: 3     Fields:    Translation:Humans
    212. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84. PMID: 18183598.
      Citations: 25     Fields:    Translation:Humans
    213. Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis. 2008; 25(3):191-9. PMID: 18264782.
      Citations: 7     Fields:    Translation:AnimalsCells
    214. Ross MI, Gershenwald JE. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008 Mar; 15(3):670-3. PMID: 18228101.
      Citations: 8     Fields:    Translation:Humans
    215. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8. PMID: 18049450.
      Citations: 10     Fields:    Translation:HumansCells
    216. Cormier JN, Xing Y, Ding M, Cantor SB, Salter KJ, Lee JE, Mansfield PF, Gershenwald JE, Ross MI. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007 Jun 10; 25(17):2442-8. PMID: 17557957.
      Citations: 11     Fields:    Translation:Humans
    217. Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8. PMID: 17328085.
      Citations: 5     Fields:    Translation:Humans
    218. Scolyer RA, Murali R, Gershenwald JE, Cochran AJ, Thompson JF. Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Ann Oncol. 2007 Apr; 18(4):806-8. PMID: 17389530.
      Citations: 2     Fields:    Translation:Humans
    219. Choi EA, Gershenwald JE. Imaging studies in patients with melanoma. Surg Oncol Clin N Am. 2007 Apr; 16(2):403-30. PMID: 17560520.
      Citations: 11     Fields:    Translation:Humans
    220. Gershenwald JE, Ross MI. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol. 2007 May; 4(5):278-9. PMID: 17389881.
      Citations: 2     Fields:    
    221. Doherty SD, George S, Prieto VG, Gershenwald JE, Duvic M. Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online J. 2006 Dec 10; 12(7):22. PMID: 17459308.
      Citations: 1     Fields:    Translation:Humans
    222. Gannon CJ, Rousseau DL, Ross MI, Johnson MM, Lee JE, Mansfield PF, Cormier JN, Prieto VG, Gershenwald JE. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52. PMID: 17063497.
      Citations: 12     Fields:    Translation:Humans
    223. Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32. PMID: 17164380.
      Citations: 34     Fields:    Translation:HumansCells
    224. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006 Nov 15; 12(22):6709-15. PMID: 17121890.
      Citations: 32     Fields:    Translation:HumansCells
    225. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14. PMID: 17000949.
      Citations: 67     Fields:    Translation:Humans
    226. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80. PMID: 16990805.
      Citations: 19     Fields:    Translation:Humans
    227. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ. Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia. 2006 Sep; 8(9):747-57. PMID: 16984732.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    228. Tellez CS, Davis DW, Prieto VG, Gershenwald JE, Johnson MM, McCarty MF, Bar-Eli M. Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. J Invest Dermatol. 2007 Feb; 127(2):387-93. PMID: 16946713.
      Citations: 22     Fields:    Translation:HumansCells
    229. Pawlik TM, Erasmus JJ, Truong MT, Macapinlac H, Ross MI, Gershenwald JE. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9. PMID: 16794124.
      Citations:    Fields:    Translation:Humans
    230. Aloia TA, Gershenwald JE, Andtbacka RH, Johnson MM, Schacherer CW, Ng CS, Cormier JN, Lee JE, Ross MI, Mansfield PF. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65. PMID: 16782925.
      Citations: 10     Fields:    Translation:Humans
    231. Witte MH, Jones K, Wilting J, Dictor M, Selg M, McHale N, Gershenwald JE, Jackson DG. Structure function relationships in the lymphatic system and implications for cancer biology. Cancer Metastasis Rev. 2006 Jun; 25(2):159-84. PMID: 16770531.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    232. Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, Ross MI, Cormier JN. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9. PMID: 16788750.
      Citations: 32     Fields:    Translation:Humans
    233. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20. PMID: 16568458.
      Citations: 23     Fields:    Translation:Humans
    234. Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, G Coit D. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006 Jun; 13(6):809-16. PMID: 16604476.
      Citations: 30     Fields:    Translation:Humans
    235. Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE, Pockaj B, Hoekstra HJ, Garberoglio C, White RL, Chu D, Biel M, Charney K, Wanebo H, Avisar E, Vetto J, Soong SJ. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):370-3. PMID: 16618904.
      Citations: 12     Fields:    Translation:Humans
    236. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006 Mar 15; 66(6):3188-96. PMID: 16540670.
      Citations: 163     Fields:    Translation:HumansAnimals
    237. Pawlik TM, Ross MI, Prieto VG, Ballo MT, Johnson MM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006 Feb 15; 106(4):900-6. PMID: 16411225.
      Citations: 19     Fields:    Translation:Humans
    238. Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei Q. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31. PMID: 16368944.
      Citations: 14     Fields:    Translation:HumansCells
    239. Ballo MT, Ross MI, Cormier JN, Myers JN, Lee JE, Gershenwald JE, Hwu P, Zagars GK. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13. PMID: 16182463.
      Citations: 15     Fields:    Translation:Humans
    240. Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, Ross MI, Du XL. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62. PMID: 16135473.
      Citations: 17     Fields:    Translation:Humans
    241. Ballo MT, Garden AS, Myers JN, Lee JE, Diaz EM, Sturgis EM, Morrison WH, Gershenwald JE, Ross MI, Weber RS, Ang KK. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21. PMID: 15952196.
      Citations: 6     Fields:    Translation:Humans
    242. Aloia TA, Gershenwald JE. Management of early-stage cutaneous melanoma. Curr Probl Surg. 2005 Jul; 42(7):460-534. PMID: 16099230.
      Citations: 1     Fields:    Translation:Humans
    243. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, Lee JE, Cormier JN, Gershenwald JE. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96. PMID: 16021533.
      Citations: 43     Fields:    Translation:Humans
    244. Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol. 2005 Apr; 31(3):323-4. PMID: 15780572.
      Citations:    Fields:    Translation:Humans
    245. Ballo MT, Zagars GK, Gershenwald JE, Lee JE, Mansfield PF, Kim KB, Camacho LH, Hwu P, Ross MI. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84. PMID: 15576833.
      Citations: 7     Fields:    Translation:Humans
    246. Daley MD, Norman PH, Leak JA, Nguyen DT, Bui TP, Kowalski AM, Srejic U, Popat K, Arens JF, Gershenwald JE, Hunt KK, Kuerer HM. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth. 2004 Aug; 16(5):332-41. PMID: 15374553.
      Citations: 4     Fields:    Translation:Humans
    247. McMasters KM, Noyes RD, Reintgen DS, Goydos JS, Beitsch PD, Davidson BS, Sussman JJ, Gershenwald JE, Ross MI. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004 Jul 01; 86(4):212-23. PMID: 15221928.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    248. Rousseau DL, Gershenwald JE. The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol. 2004 Jun; 31(3):415-25. PMID: 15190500.
      Citations:    Fields:    Translation:Humans
    249. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4. PMID: 15195788.
      Citations: 75     Fields:    Translation:Humans
    250. Pawlik TM, Ross MI, Gershenwald JE. Lymphatic mapping in the molecular era. Ann Surg Oncol. 2004 Apr; 11(4):362-74. PMID: 15070595.
      Citations: 2     Fields:    Translation:Humans
    251. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, Broemeling LD, Johnson MM, Ballo MT, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Prieto VG, Bedikian AY. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83. PMID: 15042682.
      Citations: 24     Fields:    Translation:Humans
    252. Bonnen MD, Ballo MT, Myers JN, Garden AS, Diaz EM, Gershenwald JE, Morrison WH, Lee JE, Oswald MJ, Ross MI, Ang KK. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004 Jan 15; 100(2):383-9. PMID: 14716775.
      Citations: 8     Fields:    Translation:Humans
    253. Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4. PMID: 14675203.
      Citations: 12     Fields:    Translation:Humans
    254. Kawai Y, Takeda A, Gershenwald JE. [Effects of vascular endothelial growth factor D on the signaling cascade of sentinel lymphatic endothelial cells from melanoma patients undergoing sentinel lymphadenectomy]. Gan To Kagaku Ryoho. 2003 Dec; 30(13):2141-4. PMID: 14712780.
      Citations:    Fields:    Translation:HumansCells
    255. McCarty MF, Bielenberg DR, Nilsson MB, Gershenwald JE, Barnhill RL, Ahearne P, Bucana CD, Fidler IJ. Epidermal hyperplasia overlying human melanoma correlates with tumour depth and angiogenesis. Melanoma Res. 2003 Aug; 13(4):379-87. PMID: 12883364.
      Citations: 6     Fields:    Translation:HumansAnimals
    256. Rousseau DL, Ross MI, Johnson MM, Prieto VG, Lee JE, Mansfield PF, Gershenwald JE. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74. PMID: 12794025.
      Citations: 28     Fields:    Translation:Humans
    257. Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, Cremona F, Gershenwald JE, Chase JL, Lozano RD, Patt YZ, Fornage BD, Vauthey JN, Woodall ML, Gonzalez KB, Ellis LM. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003 May; 10(4):348-54. PMID: 12734081.
      Citations: 7     Fields:    Translation:Humans
    258. Ballo MT, Bonnen MD, Garden AS, Myers JN, Gershenwald JE, Zagars GK, Schechter NR, Morrison WH, Ross MI, Kian Ang K. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96. PMID: 12655537.
      Citations: 12     Fields:    Translation:Humans
    259. Bedrosian I, Gershenwald JE. Surgical clinical trials in melanoma. Surg Clin North Am. 2003 Apr; 83(2):385-403. PMID: 12744615.
      Citations: 1     Fields:    Translation:Humans
    260. Balch CM, Sober AJ, Soong SJ, Gershenwald JE. The new melanoma staging system. Semin Cutan Med Surg. 2003 Mar; 22(1):42-54. PMID: 12773013.
      Citations: 5     Fields:    Translation:Humans
    261. Amato M, Esmaeli B, Ahmadi MA, Tehrani MH, Gershenwald J, Ross M, Holds J, Delpassand E. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar; 19(2):102-6. PMID: 12644754.
      Citations: 6     Fields:    Translation:Humans
    262. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15. PMID: 12591987.
      Citations: 46     Fields:    Translation:HumansCells
    263. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52. PMID: 12923915.
      Citations: 20     Fields:    Translation:Humans
    264. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA, Bedikian AY, Kim KB, Papadopoulos NE, Prieto VG, Ross MI. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8. PMID: 12454112.
      Citations: 34     Fields:    Translation:Humans
    265. Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei Q. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3. PMID: 12376526.
      Citations: 8     Fields:    Translation:HumansCells
    266. Sumner WE, Ross MI, Mansfield PF, Lee JE, Prieto VG, Schacherer CW, Gershenwald JE. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002 Jul 15; 95(2):354-60. PMID: 12124836.
      Citations: 14     Fields:    Translation:Humans
    267. Lee JE, Abdalla J, Porter GA, Bradford L, Grimm EA, Reveille JD, Mansfield PF, Gershenwald JE, Ross MI. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93. PMID: 12095976.
      Citations: 8     Fields:    Translation:Humans
    268. Gershenwald JE, Fidler IJ. Cancer. Targeting lymphatic metastasis. Science. 2002 Jun 07; 296(5574):1811-2. PMID: 12052939.
      Citations: 11     Fields:    Translation:HumansAnimals
    269. Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):964-72. PMID: 11958890.
      Citations: 13     Fields:    Translation:Humans
    270. Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Gershenwald JE, Coit DG, McMasters KM, Balch CM, Reintgen D. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70. PMID: 11776489.
      Citations: 12     Fields:    Translation:Humans
    271. Esmaeli B, Wang X, Youssef A, Gershenwald JE. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001 Nov; 108(11):2101-5. PMID: 11713086.
      Citations: 27     Fields:    Translation:Humans
    272. Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy for conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2001 Nov; 17(6):436-42. PMID: 11766025.
      Citations: 9     Fields:    Translation:Humans
    273. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48. PMID: 11504745.
      Citations: 439     Fields:    Translation:Humans
    274. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, Bar-Eli M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene. 2001 Jun 07; 20(26):3363-75. PMID: 11423987.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    275. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, Fenske N, Glass F, Balch CM, Coit DG. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001 Jun 01; 19(11):2851-5. PMID: 11387357.
      Citations: 17     Fields:    Translation:Humans
    276. McMasters KM, Reintgen DS, Ross MI, Wong SL, Gershenwald JE, Krag DN, Noyes RD, Viar V, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001 Apr; 8(3):192-7. PMID: 11314933.
      Citations: 19     Fields:    Translation:Humans
    277. Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22. PMID: 11258775.
      Citations: 16     Fields:    Translation:Humans
    278. Gershenwald JE. Melanoma. Oncologist. 2001; 6(5):402-6. PMID: 11675517.
      Citations:    Fields:    Translation:Humans
    279. Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Clin Lab Med. 2000 Dec; 20(4):785-815. PMID: 11221515.
      Citations: 1     Fields:    Translation:Humans
    280. Porter GA, Ross MI, Berman RS, Sumner WE, Lee JE, Mansfield PF, Gershenwald JE. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery. 2000 Aug; 128(2):306-11. PMID: 10923009.
      Citations: 2     Fields:    Translation:Humans
    281. Gershenwald JE, Fischer D, Buzaid AC. Clinical classification and staging. Clin Plast Surg. 2000 Jul; 27(3):361-76, viii. PMID: 10941558.
      Citations: 2     Fields:    Translation:Humans
    282. Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000 May; 7(4):256-61. PMID: 10819364.
      Citations: 10     Fields:    Translation:Humans
    283. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91. PMID: 10717634.
      Citations: 43     Fields:    Translation:Humans
    284. Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000 Mar; 7(2):160-5. PMID: 10761797.
      Citations: 29     Fields:    Translation:Humans
    285. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83. PMID: 10071292.
      Citations: 139     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    286. Gershenwald JE, Hunt KK, Kroll SS, Ross MI, Baldwin BJ, Feig BW, Ames FC, Schusterman MA, Singletary SE. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998 Sep; 5(6):529-38. PMID: 9754762.
      Citations: 5     Fields:    Translation:Humans
    287. Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):737-65. PMID: 9759577.
      Citations: 3     Fields:    Translation:Humans
    288. Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M, Lee JJ, Ross MI. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10. PMID: 9706139.
      Citations: 21     Fields:    Translation:Humans
    289. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli M. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem. 1998 Jun 26; 273(26):16501-8. PMID: 9632718.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    290. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60. PMID: 9626228.
      Citations: 61     Fields:    Translation:Humans
    291. Heaton KM, Sussman JJ, Gershenwald JE, Lee JE, Reintgen DS, Mansfield PF, Ross MI. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998 Jun; 5(4):322-8. PMID: 9641453.
      Citations: 19     Fields:    Translation:Humans
    292. Talmor M, Hydo L, Gershenwald JG, Barie PS. Beneficial effects of chest tube drainage of pleural effusion in acute respiratory failure refractory to positive end-expiratory pressure ventilation. Surgery. 1998 Feb; 123(2):137-43. PMID: 9481398.
      Citations: 16     Fields:    Translation:Humans
    293. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997 Oct; 151(4):1105-13. PMID: 9327744.
      Citations: 108     Fields:    Translation:HumansAnimalsCells
    294. He W, Fong Y, Marano MA, Gershenwald JE, Yurt RW, Moldawer LL, Lowry SF. Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine responses. J Infect Dis. 1992 May; 165(5):859-64. PMID: 1569335.
      Citations: 15     Fields:    Translation:Animals
    295. Fong Y, Moldawere LL, He W, Marano M, Keogh CV, Gershenwald J, Lowry SF. Tumour location influences local cytokine production and host metabolism. Surg Oncol. 1992 Feb; 1(1):65-71. PMID: 1341237.
      Citations: 4     Fields:    Translation:Animals
    296. Gershenwald JE, Fong YM, Fahey TJ, Calvano SE, Chizzonite R, Kilian PL, Lowry SF, Moldawer LL. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A. 1990 Jul; 87(13):4966-70. PMID: 1695006.
      Citations: 35     Fields:    Translation:Animals
    297. Gershenwald JE, Bensadoun A, Saluja A. Monoclonal antibodies to avian lipoprotein lipase. Purification of the enzyme by immunoaffinity chromatography. Biochim Biophys Acta. 1985 Oct 02; 836(3):286-95. PMID: 4041471.
      Citations:    Fields:    Translation:Animals
    298. Melanoma prevention-avoiding indoor tanning and minimizing overexposure to the sun. JAMA - Journal of the American Medical Association. 316:1913-1914.
    299. CDC Grand Rounds. American Journal of Transplantation. 16:717-720.
    300. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer Journal for Clinicians.
    301. Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology. 1-9.
    302. Reply to J.M. Thomas et al. Journal of Clinical Oncology. 28.
    303. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. New England Journal of Medicine. 370:663-664.
    304. Influence of tumor location on cytokine production and host metabolism. Surgical Forum. 41:450-452.
    305. State of the science on prevention and screening to reduce melanoma incidence and mortality. CA Cancer Journal for Clinicians.
    306. Melanoma. 633-652.
    307. Melanoma Expression Genes Identified through Genome-Wide Association Study of Breslow Tumor Thickness. Journal of Investigative Dermatology. 137:253-257.
    308. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma. Melanoma Research.
    309. Cutaneous melanoma. 153-165.
    310. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine. 14.
    311. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (United States). 95.
    312. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma. Journal of the National Cancer Institute. 108.
    313. Differential metabolic response of myocardial versus skeletal muscle during catabolic postburn infection. Surgical Forum. 40:50-52.
    314. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.
    315. The authors reply. New England Journal of Medicine. 365:571.
    316. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell and Melanoma Research.
    317. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. European Journal of Cancer Care. 24:724-733.
    318. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clinical Cancer Research. 15:7538-7546.
    319. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    320. Inflammatory marker testing identifies CD74 expression in melanoma tumor cells, and its expression associates with favorable survival for stage III melanoma. Clinical Cancer Research. 22:3016-3024.
    321. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. Journal of Surgical Oncology. 112:834-840.
    322. Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. American Journal of Preventive Medicine.
    323. Melanoma survivorship management. 219-239.
    324. The Eighth Edition AJCC Cancer Staging Manual. CA Cancer Journal for Clinicians.
    325. Association of Vitamin D levels with outcome in patients with melanoma after adjustment for C-reactive protein. Journal of Clinical Oncology. 34:1741-1747.
    326. Future perspectives in melanoma research. Journal of Translational Medicine. 12.
    327. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. Journal of Investigative Dermatology.
    328. Cancer Discovery. 6:202-216.
    329. Journal of Investigative Dermatology. 136:1894-1897.
    330. In reply. Journal of Clinical Oncology. 26:6012.
    331. Clinicopathological features and clinical outcomes associated with TP53 and BRAFN on- V 600 mutations in cutaneous melanoma patients. Cancer.
    332. Introduction. Operative Techniques in General Surgery. 8:65.
    GERSHENWALD's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (743)
    Explore
    _
    Co-Authors (181)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _